A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
32
Final Accrual
32
Closing Date of Accrual
22 November 2022
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
14 April, 2026
Consumer Engagement Charter cements TROG’s commitment to listen to consumer voices
LATEST NEWS: 14 April 2026 TROG has made a
9 April, 2026
Vale Professor Jim Denham OAM, TROG founder and world-class researcher
9 April 2026 TROG Cancer Research honours the life